Sensus Healthcare (NASDAQ:SRTS) Raised to “Strong-Buy” at Roth Capital

Roth Capital upgraded shares of Sensus Healthcare (NASDAQ:SRTS) to a strong-buy rating in a report published on Friday, Zacks.com reports. Roth Capital also issued estimates for Sensus Healthcare’s Q4 2025 earnings at $0.21 EPS, FY2026 earnings at $0.60 EPS and FY2027 earnings at $0.69 EPS.

Several other brokerages also recently weighed in on SRTS. Maxim Group lifted their price objective on shares of Sensus Healthcare from $7.00 to $10.00 and gave the company a buy rating in a research report on Friday, May 10th. HC Wainwright lifted their price objective on shares of Sensus Healthcare from $8.00 to $10.00 and gave the company a buy rating in a research report on Monday, May 13th.

Sensus Healthcare Price Performance

Shares of SRTS stock opened at $6.17 on Friday. The firm has a market cap of $101.14 million, a P/E ratio of 21.28 and a beta of 1.00. Sensus Healthcare has a 1-year low of $1.79 and a 1-year high of $6.55. The firm has a fifty day moving average of $5.37 and a two-hundred day moving average of $4.18.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, May 9th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.18. The company had revenue of $10.66 million during the quarter, compared to analyst estimates of $4.33 million. Sensus Healthcare had a net margin of 14.70% and a return on equity of 9.76%. During the same period last year, the business earned ($0.12) EPS. On average, sell-side analysts expect that Sensus Healthcare will post 0.29 EPS for the current year.

Insider Activity at Sensus Healthcare

In other news, Director John Heinrich sold 15,227 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $6.24, for a total value of $95,016.48. Following the sale, the director now owns 59,940 shares of the company’s stock, valued at approximately $374,025.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 11.10% of the company’s stock.

Institutional Trading of Sensus Healthcare

A number of hedge funds have recently modified their holdings of the company. Creekmur Asset Management LLC acquired a new stake in Sensus Healthcare during the 4th quarter worth approximately $83,000. Hillsdale Investment Management Inc. acquired a new stake in Sensus Healthcare during the 1st quarter worth approximately $155,000. Finally, Sachetta LLC acquired a new stake in Sensus Healthcare during the 4th quarter worth approximately $247,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.